Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 244.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 589,471 shares of the company's stock after buying an additional 418,139 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.38% of Xeris Biopharma worth $3,236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently bought and sold shares of the business. Deutsche Bank AG lifted its position in Xeris Biopharma by 492.8% in the first quarter. Deutsche Bank AG now owns 756,407 shares of the company's stock valued at $4,153,000 after acquiring an additional 628,807 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of Xeris Biopharma by 5.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 423,775 shares of the company's stock valued at $2,327,000 after purchasing an additional 20,903 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Xeris Biopharma by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company's stock valued at $44,522,000 after purchasing an additional 210,581 shares during the last quarter. R Squared Ltd lifted its holdings in shares of Xeris Biopharma by 27.7% in the 1st quarter. R Squared Ltd now owns 15,730 shares of the company's stock valued at $86,000 after purchasing an additional 3,410 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Xeris Biopharma in the 1st quarter valued at about $1,187,000. 42.75% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several analysts have recently weighed in on the company. Wall Street Zen raised Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. HC Wainwright raised shares of Xeris Biopharma to a "buy" rating and set a $10.00 target price on the stock in a report on Tuesday, August 12th. Finally, Oppenheimer lifted their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Xeris Biopharma has a consensus rating of "Buy" and an average price target of $6.58.
Read Our Latest Report on Xeris Biopharma
Insider Transactions at Xeris Biopharma
In other Xeris Biopharma news, insider Kevin Mcculloch bought 25,000 shares of the business's stock in a transaction dated Friday, June 13th. The stock was acquired at an average cost of $4.38 per share, with a total value of $109,500.00. Following the purchase, the insider owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. This represents a 1.48% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director John Johnson sold 107,500 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $7.32, for a total value of $786,900.00. Following the transaction, the director directly owned 833,483 shares of the company's stock, valued at approximately $6,101,095.56. This trade represents a 11.42% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 4.56% of the company's stock.
Xeris Biopharma Stock Down 2.8%
XERS traded down $0.22 on Monday, hitting $7.47. 1,004,305 shares of the company traded hands, compared to its average volume of 2,566,623. The company has a 50 day moving average of $5.23 and a 200-day moving average of $4.72. The stock has a market capitalization of $1.21 billion, a PE ratio of -35.55 and a beta of 0.65. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.48 and a 12-month high of $7.79.
Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts' expectations of $64.58 million. On average, research analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.
About Xeris Biopharma
(
Free Report)
Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Featured Stories
Before you consider Xeris Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xeris Biopharma wasn't on the list.
While Xeris Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
